1-3 of 3
Yunnan Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Robert Zeiser, Raynier Devillier, Maria Caterina Mico', David Valcarcel, Simon Call, Christian Niederwieser, Claire Nourry, Yunnan Xu, Thierry Medts, Nathalie Guichard, Hans D. Menssen, Nicola Polverelli
Journal: Blood
Blood (2023) 142 (Supplement 1): 59.
https://doi.org/10.1182/blood-2023-180876
Published: 2023
Journal Articles

Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial

Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Jason E Farrar, Sujith Samarasinghe, Brigitte Strahm, Winfred C. Wang, Adrianna Vlachos, Charlotte M. Niemeyer, Timothy S. Olson, Denise D'Alessio, Elise Burmeister Getz, Tomasz Lawniczek, Yunnan Xu, David A. Williams
Journal: Blood
Blood (2022) 140 (Supplement 1): 705–707.
https://doi.org/10.1182/blood-2022-158214
Published: 2022
Journal Articles

Siremadlin in Combination with Venetoclax (VEN) Plus Azacitidine (AZA) in Adult Patients with Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy: A Phase Ib/II Trial

Naval Daver, Andrew H. Wei, Eytan Stein, Daniel J. DeAngelo, Dhrubajyoti Pathak, Yunnan Xu, Stephanie Grzesiak, Adriano Venditti
Journal: Blood
Blood (2022) 140 (Supplement 1): 11625–11627.
https://doi.org/10.1182/blood-2022-167326
Published: 2022